Athersys Appoints Joseph Nolan to Its Board of Directors
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Joseph “Joe” Nolan to its Board of Directors, effective January 4, 2023.
- Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Joseph “Joe” Nolan to its Board of Directors, effective January 4, 2023.
- Mr. Nolan is an experienced biotechnology and pharmaceutical executive who currently serves as Chief Executive Officer of Jaguar Gene Therapy, LLC.
- With this appointment, Athersys has five Directors, four of whom are independent.
- “I’m proud to join the Athersys Board and am enthusiastic about MultiStem’s potential across a range of unmet medical needs.